2009
DOI: 10.1016/j.addbeh.2008.11.007
|View full text |Cite
|
Sign up to set email alerts
|

Schizotypy and nicotine, alcohol, and cannabis use in a non-psychiatric sample

Abstract: Esterberg, Michael L.; Goulding, Sandra M.; McClure-Tone, Erin B.; and Compton, Michael T., "Schizotypy and Nicotine, Alcohol, and Cannabis Use in a Non-Psychiatric Sample" (2009). Psychology Faculty Publications. Paper 131.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
45
1
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 51 publications
(53 citation statements)
references
References 20 publications
(11 reference statements)
6
45
1
1
Order By: Relevance
“…Inter-correlations between the SPQ domain scores, PAS score, and SAS score are shown in Table 3. Also, as previously reported (Esterberg et al, 2009), correlations between the four SPQ domains were quite high (r=.43-.84), though it should be noted that the highest correlation is largely driven by overlap among two subscales (paranoid ideation/suspiciousness and excessive social anxiety) in the paranoid and negative domains (the only overlapping domains).…”
Section: Resultssupporting
confidence: 48%
See 1 more Smart Citation
“…Inter-correlations between the SPQ domain scores, PAS score, and SAS score are shown in Table 3. Also, as previously reported (Esterberg et al, 2009), correlations between the four SPQ domains were quite high (r=.43-.84), though it should be noted that the highest correlation is largely driven by overlap among two subscales (paranoid ideation/suspiciousness and excessive social anxiety) in the paranoid and negative domains (the only overlapping domains).…”
Section: Resultssupporting
confidence: 48%
“…In particular, the standard 3-factor model of Raine et al (1994) Internal consistency reliability coefficients for domain scores derived using the best fitting 4-factor model ranged .81-.89 ( Table 3). As documented in a prior report on schizotypy and substance use in this sample (Esterberg et al, 2009), mean (± standard deviation) scores for the cognitive-perceptual, paranoid, negative, and disorganized subscales were 3.9±3.4, 9.8±5.6, 9.9±6.8, and 5.3±4.1, respectively. Correlations between the SPQ total score and the PAS and SAS were r=.38 and r=.30, respectively, and the correlation between PAS and SAS scores was r=.21.…”
Section: Resultsmentioning
confidence: 65%
“…A varying degree of illegal and legal drug consumption along the SSp might explain heterogeneous findings when investigating the link between schizotypy and neuropsychological performance (Archie et al, 2007;Barnes et al, 2006;Esterberg et al, 2009;Gurpegui et al, 2004;Jones & Fernyhough, 2009;de Leon et al, 2002;Williams, Wellman, Allan, et al, 1996). In particular, it could be conjectured that neuropsychological impairments formerly associated with symptom dimensions are actually the result of drug use.…”
Section: Discussionmentioning
confidence: 94%
“…Of particular interest to the present study is the enhanced consumption of readily available psychoactive substances as one moves along the SSp, such as i) tobacco in schizotypy (Esterberg, Goulding, McClure-Tone, & Compton, 2009;Williams, Wellman, Allan, et al, 1996) and schizophrenia patients (de Leon, Diaz, Rogers, Browne, & Dinsmore, 2002), ii) cannabis in schizotypy (Barkus, Stirling, Hopkins, & Lewis, 2006;Skosnik, Spatz-Glenn, & Park, 2001;Williams, Wellman, & Rawlins, 1996) and schizophrenia (Barnes, Mutsatsa, Hutton, Watt, & Joyce, 2006), and iii) caffeine in schizotypy (Jones & Fernyhough, 2009) and schizophrenia (Gurpegui, Aguilar, Martinez-Ortega, Diaz, & de Leon, 2004). While some authors have suggested that dopamineenhancing drugs such as nicotine (Montgomery, Lingford-Hughes, Egerton, Nutt, & Grasby, 2007;Murphy et al, 2002) might be involved in the development of psychosis or some aspects of it (Abi-Dargham et al, 1998;Moore et al, 2007;Smith et al, 2009), others suggest that at-risk individuals may use nicotine as means of self medication (Adler, Hoffer, Wiser, & Freedman, 1993;Kumari & Postma, 2005;Zabala et al, 2009;Zammit et al, 2003).…”
Section: Introductionmentioning
confidence: 99%
“…In a Norwegian study of substance abuse treatment retention several years ago, schizotypal traits predicted treatment dropout 87 , but we have not found more recent studies of schizotypal personality disorder and SUD treatment outcome. However, the strong cross-sectional relationship between schizotypal personality disorder and substance use disorders 22, 27, 88 is drawing increased attention 88 Given the interest in cannabis use as a risk factor for schizophrenia and the connection of schizotypal personality disorder to schizophrenia in the schizophrenia-spectrum domain, several cross-sectional studies examined the association between cannabis use and schizotypal symptoms, finding positive associations 89-95 . The only study among these to address time order found that the schizotypal symptoms preceded cannabis use 91 , suggesting that this association is not an artifact of cannabis effects.…”
Section: Discussionmentioning
confidence: 99%